Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients (NCT04054999) (2024)

Government Record · Mayo Clinic (lead sponsor); Sher-Lu Pai (responsible party); U.S. National Library of Medicine (registry) · June 24, 2024

Mayo Clinic (lead sponsor), 2024-06-24: Registry record for a completed Mayo Clinic Phase 4 randomised open-label pilot (19 patients) comparing hydroxocobalamin with methylene blue for intraoperative vasoplegia in liver transplantation; lead sponsor Mayo Clinic, an academic centre, with results posted in 2024.

The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

Mayo Clinic (lead sponsor), 2024-06-24: Registry record for a completed Mayo Clinic Phase 4 randomised open-label pilot (19 patients) comparing hydroxocobalamin with methylene blue for intraoperative vasoplegia in liver transplantation; lead sponsor Mayo Clinic, an academic centre, with results posted in 2024. C4 funding. Lead sponsor Mayo Clinic (class OTHER); responsible party Sher-Lu Pai, PI; no industry sponsor or collaborator listed. Phase 4, randomised, open-label, N=19 actual, start 2019-11-30, completion 2024-02-27, results first posted 2024-06-24; intervention comparator hydroxocobalamin (Cyanokit). Record fields transcribed from the registry JSON (briefTitle / design / sponsor / status fields) – not prose. The human /study/ page is JavaScript-rendered, so the machine-readable api/v2 record is cited so the field is checkable. text_file=B_13.txt